Instructions: In this task, you're given a question, along with three passages, 1, 2, and 3. Your job is to determine which passage can be used to answer the question by searching for further information using terms from the passage. Indicate your choice as 1, 2, or 3.
Input: Question: Was flosequinan ever approved? Passage 1:The Tampa Bay Rays selected Faria in the 10th round of the 2011 Major League Baseball draft. He made his professional debut with the Gulf Coast Rays. Faria played 2012 and 2013 with the Princeton Rays. He pitched 2014 with the Bowling Green Hot Rods and started 2015 with the Charlotte Stone Crabs. After going 10–1 with a 1.33 earned run average (ERA) in 12 games, he was promoted to the Double-A Montgomery Biscuits. In his second start with Montgomery tied a team record with 14 strikeouts over seven no-hit innings. Faria started 2016 with Montgomery and was called to the Durham Bulls in June. Entering the 2017 Season, Faria was considered by Baseball America to be the 8th best prospect in the Rays farm system.. He started the season with the Bulls, and was promoted to the Rays on June 6.
 Passage 2:Z33 was a Type 1936A (Mob) destroyer built for the Kriegsmarine (German Navy) during World War II. Completed in 1943, the ship was damaged during the raid on the island of Spitsbergen in September and spent all of 1944 in Norwegian waters. She was damaged by British aircraft attacking the battleship in July. Z33 escorted troop convoys from northern Norway when the Germans began evacuating the area beginning in October. She ran aground in early 1945 as she was sailing for the Baltic and was badly damaged. While the ship was being towed to port for repairs, she and her escorts were attacked by Allied fighter-bombers. Z33 finally reached the Baltic in early April, but was reduced to reserve for lack of fuel. The ship was transferred to Cuxhaven and decommissioned shortly before the end of the war.
 Passage 3:He was principal investigator on the REFLECT trial for flosequinan which ran from 1987-1989 and the following PROFILE trial from 1991-1994. He was PI on a study of amlodipine that ran from 1987-1989 and the following PRAISE trial from 1992-1995 and PRAISE 2 from 1996-1999; the PROMISE trial for milrinone 1988-1990; the ATLAS trial for lisinopril from 1993-1997; the PRECISE trial for carvedilol from 1993-1995 and the following COPERNICUS trial from 1997-2002; the ENABLE trial (1999-2001) and REACH-1 trial (1997-2003) for bosentan; the OVERTURE trial (1999-2002) for omapatrilat; REVIVE I and II (2001-2006) for levosimendan; and the TRUE-AHF trial of ularitide that started in 2013. He also chaired the steering committee for the RADIANCE trial from 1989-1992 which studied the use of digoxin in people who were also treated with ACE inhibitors and chaired the steering committee for the RENEWAL trial (1999-2002) for etanercept. He was also the co-PI of the PARADIGM-HF trial that led to the approval of valsartan/sacubitril.

Output:
3